Evidence map›Paper›PMID 33236256›Full record

ArticleAmino acids2021

The introduction of L-phenylalanine into antimicrobial peptide protonectin enhances the selective antibacterial activity of its derivative phe-Prt against Gram-positive bacteria.

Jinxiu Peng, Shuai Qiu, Fengjing Jia, Lishi Zhang, Yuhang He, Fangfang Zhang, Mengmeng Sun, Yabo Deng, Yifei Guo, Zhaoqing Xu and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Amino acids, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Chinese herbal medicines · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Optimization of Flavonoid Extraction fromMolecules (Basel, Switzerland) · 2021
    Article
  6. Antimicrobial Peptides: A Potent Alternative to Antibiotics.Antibiotics (Basel, Switzerland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Jinxiu PengKey laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Research Unit of Peptide Science of Chinese Academy of Medical Sciences 2019RU066, Lanzhou University, Lanzhou, People's Republic of China.
Shuai QiuKey laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Research Unit of Peptide Science of Chinese Academy of Medical Sciences 2019RU066, Lanzhou University, Lanzhou, People's Republic of China.
Fengjing JiaKey laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Research Unit of Peptide Science of Chinese Academy of Medical Sciences 2019RU066, Lanzhou University, Lanzhou, People's Republic of China.
Lishi ZhangKey laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Research Unit of Peptide Science of Chinese Academy of Medical Sciences 2019RU066, Lanzhou University, Lanzhou, People's Republic of China.
Yuhang HeKey laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Research Unit of Peptide Science of Chinese Academy of Medical Sciences 2019RU066, Lanzhou University, Lanzhou, People's Republic of China.
Fangfang ZhangKey Laboratory for Gynecologic Oncology of Gansu Province, Department of Gynecology, The First Hospital of Lanzhou University, Lanzhou University, Lanzhou, People's Republic of China.
Mengmeng SunKey laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Research Unit of Peptide Science of Chinese Academy of Medical Sciences 2019RU066, Lanzhou University, Lanzhou, People's Republic of China.
Yabo DengKey laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Research Unit of Peptide Science of Chinese Academy of Medical Sciences 2019RU066, Lanzhou University, Lanzhou, People's Republic of China.
Yifei GuoKey laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Research Unit of Peptide Science of Chinese Academy of Medical Sciences 2019RU066, Lanzhou University, Lanzhou, People's Republic of China.
Zhaoqing XuKey laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Research Unit of Peptide Science of Chinese Academy of Medical Sciences 2019RU066, Lanzhou University, Lanzhou, People's Republic of China.
Xiaolei LiangKey Laboratory for Gynecologic Oncology of Gansu Province, Department of Gynecology, The First Hospital of Lanzhou University, Lanzhou University, Lanzhou, People's Republic of China.
Wenjin YanKey laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Research Unit of Peptide Science of Chinese Academy of Medical Sciences 2019RU066, Lanzhou University, Lanzhou, People's Republic of China. yanwj@lzu.edu.cn.
Kairong WangKey laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Research Unit of Peptide Science of Chinese Academy of Medical Sciences 2019RU066, Lanzhou University, Lanzhou, People's Republic of China. wangkr@lzu.edu.cn.ORCID http://orcid.org/0000-0003-0749-9214
Chinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Hospital of Lanzhou University · CN

Funding

Fundamental Research Funds for the Central Universities lzujbky-2020- kb13National Natural Science Foundation of China 81601351National Natural Science Foundation of China 81872723National Natural Science Foundation of China 82073679Natural Science Foundation of Gansu Province (CN) 20JR5RA245
6 · The paper itself

Abstract

Protonectin was a typical amphiphilic antimicrobial peptide with potent antimicrobial activity against Gram-positive and Gram-negative bacteria. In the present study, when its eleventh amino acid in the sequence was substituted by phenylalanine, the analog named phe-Prt showed potent antimicrobial activity against Gram-positive bacteria, but no antimicrobial activity against Gram-negative bacteria, indicating a significant selectivity between Gram-positive bacteria and Gram-negative bacteria. However, when Gram-negative bacteria were incubated with EDTA, the bacteria were susceptible to phe-Prt. Next, the binding effect of phe-Prt with LPS was determined. Our result showed that LPS could hamper the bactericidal activity of phe-Prt against Gram-positive bacteria. The result of zeta potential assay further confirmed the binding effect of phe-Prt with LPS for it could neutralize the surface charge of E. coli and LPS. Then, the effect of phe-Prt on the integrity of outer membrane of Gram-negative bacteria was determined. Our results showed that phe-Prt had a much weaker disturbance to the outer membrane of Gram-negative bacteria than the parent peptide protonectin. In summary, the introduction of L-phenylalanine into the sequence of antimicrobial peptide protonectin made phe-Prt show significant selectivity against Gram-positive bacteria, which could partly be attributed to the delay effect of LPS for phe-Prt to access to cell membrane. Although further study is still needed to clarify the exact mechanism of selectivity, the present study provided a strategy to develop antimicrobial peptides with selectivity toward Gram-positive and Gram-negative bacteria.

Indexed as

Anti-Bacterial AgentsCell MembraneCell Membrane PermeabilityCircular DichroismGram-Negative BacteriaGram-Positive BacteriaLipopolysaccharidesMicrobial Sensitivity TestsMicrobial ViabilityOligopeptidesPhenylalaninePore Forming Cytotoxic ProteinsWasp VenomsAnti-Bacterial AgentsLipopolysaccharidesOligopeptidesPhenylalaninePore Forming Cytotoxic Proteinsprotonectin (1-6), Agelaia pallipes pallipesWasp VenomsAntimicrobial peptide phe-PrtGram-negative bacteriaLPSSelectivity

Identifiers

PMID33236256
OpenAlexW3107194576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.